Caladrius Biosciences (NASDAQ:CLBS) Upgraded at ValuEngine

ValuEngine upgraded shares of Caladrius Biosciences (NASDAQ:CLBS) from a hold rating to a buy rating in a research note released on Thursday, ValuEngine reports.

Several other brokerages have also commented on CLBS. WBB Securities initiated coverage on shares of Caladrius Biosciences in a research report on Tuesday, May 14th. They issued a speculative buy rating and a $6.75 price objective on the stock. Chardan Capital reaffirmed a buy rating and issued a $6.00 price objective on shares of Caladrius Biosciences in a research report on Sunday, May 12th. Finally, Zacks Investment Research raised shares of Caladrius Biosciences from a sell rating to a buy rating and set a $3.25 price objective on the stock in a research report on Friday, July 19th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of Buy and a consensus target price of $8.63.

Shares of CLBS traded down $0.15 during trading hours on Thursday, reaching $2.67. 9,316 shares of the stock traded hands, compared to its average volume of 47,495. The stock has a fifty day moving average price of $2.70. Caladrius Biosciences has a 52 week low of $2.16 and a 52 week high of $6.83.

Caladrius Biosciences (NASDAQ:CLBS) last announced its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.05). As a group, analysts predict that Caladrius Biosciences will post -1.51 earnings per share for the current year.

A hedge fund recently bought a new stake in Caladrius Biosciences stock. Wesbanco Bank Inc. bought a new position in Caladrius Biosciences Inc (NASDAQ:CLBS) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 10,000 shares of the biotechnology company’s stock, valued at approximately $36,000. Wesbanco Bank Inc. owned approximately 0.10% of Caladrius Biosciences as of its most recent SEC filing. 7.57% of the stock is currently owned by institutional investors and hedge funds.

About Caladrius Biosciences

Caladrius Biosciences, Inc is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.

Featured Story: Call Option

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with's FREE daily email newsletter.